110
Participants
Start Date
January 1, 2022
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2025
original therapy
* Patients on ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②Patients who received TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③Patients who received TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
rescue therapy
TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
RECRUITING
Ankang Central Hospital, Ankang
RECRUITING
Hanzhong 3201 Hospital, Hanzhong
RECRUITING
Qianfhan Hospital, Jinan
RECRUITING
Weinan Central Hospital, Weinan
RECRUITING
Wuhan Union Hospital, Wuhan
RECRUITING
Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
RECRUITING
Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an
RECRUITING
Shaanxi Provincial People's Hospital, Xi'an
RECRUITING
Tang-Du Hospital, Xi'an
RECRUITING
Xi'an Central Hospital, Xi'an
RECRUITING
Xijing hospital of air force Medical University, Xi'an
RECRUITING
Yan'an University Affiliated Hospital, Yan’an
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
First Affiliated Hospital Xi'an Jiaotong University
OTHER